Skip to content

Mark Lappe, Chief Executive Officer at Inhibrx Biosciences, bought INBX on Oct 14, 2026

Data as of Oct 16

▲ BUY$208K2,451 shares at $85.00Mark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.
Watch INBX
Traded
Oct 14, 2026
Disclosed
Oct 14, 2026
Filed
The same day

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Mark Lappe, Chief Executive Officer at Inhibrx Biosciences, bought INBX on Oct 14, 2026TRADEDDISCLOSED
INBXSimilar stocks (XLV — its sector index fund), rebased to INBX's price on the disclosure day
INBX since disclosure
+5.4%
Similar stocks (XLV) since disclosure
+1.6%
XLV — its sector index fund

Change in closing price from Oct 14, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$208Kdisclosed Oct 14 · filed the same day
  2. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$210Kdisclosed Oct 14 · filed the same day
  3. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$8.6Kdisclosed Oct 14 · filed the same day
  4. ▲ BUYMark Lappe Chief Executive OfficerINBX Inhibrx Biosciences, Inc.$206Kdisclosed Oct 14 · filed the same day

See every trade on INBX →